Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Arvinas, Inc. (NASDAQ:ARVN) have received a consensus rating of “Hold” from the fourteen ratings firms that are covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokers that have covered the stock in the last year is $14.6923.

ARVN has been the subject of a number of research reports. Wedbush lifted their price objective on shares of Arvinas from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Zacks Research cut shares of Arvinas from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Piper Sandler restated an “overweight” rating and issued a $20.00 price objective (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Wall Street Zen cut shares of Arvinas from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Finally, Truist Financial set a $10.00 price objective on shares of Arvinas in a report on Wednesday, March 18th.

Trending Headlines about Arvinas

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: BTIG Research raised its price target on Arvinas to $18 from $16 and reiterated a Buy rating, signaling continued Wall Street confidence in upside potential. Arvinas (NASDAQ:ARVN) Price Target Raised to $18.00 at BTIG Research
• Positive Sentiment: Arvinas and Pfizer’s breast cancer drug vepdegestrant was licensed to Rigel Pharmaceuticals in a deal that includes $85 million upfront and up to $320 million in milestones, which supports the value of Arvinas’ PROTAC platform and adds potential non-dilutive funding. Rigel strikes licensing deal for Pfizer and Arvinas’ breast cancer drug
• Neutral Sentiment: HC Wainwright modestly adjusted several earnings forecasts for Arvinas, including lower estimates for 2026-2029 and a small cut to FY2030 EPS, reflecting ongoing uncertainty around future profitability rather than a major new development.
• Neutral Sentiment: Arvinas recently beat Q1 EPS estimates, but revenue missed expectations and dropped sharply year over year, reinforcing that the company remains far from sustained profitability. Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
• Negative Sentiment: Recent insider selling by the CEO, CFO, CAO, and another executive may be pressuring sentiment, even though the sales were disclosed as tax-withholding transactions tied to equity vesting. CEO insider filing

Insider Transactions at Arvinas

In other Arvinas news, Director Briggs Morrison acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average price of $13.40 per share, for a total transaction of $268,000.00. Following the completion of the acquisition, the director owned 96,021 shares of the company’s stock, valued at approximately $1,286,681.40. This trade represents a 26.31% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Noah Berkowitz sold 11,108 shares of Arvinas stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $110,413.52. Following the completion of the transaction, the insider owned 191,395 shares of the company’s stock, valued at $1,902,466.30. This trade represents a 5.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 81,449 shares of company stock valued at $945,574. 7.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC grew its holdings in Arvinas by 50.0% during the 4th quarter. Armistice Capital LLC now owns 1,800,000 shares of the company’s stock worth $21,348,000 after acquiring an additional 600,000 shares in the last quarter. TCG Crossover Management LLC acquired a new position in Arvinas during the 3rd quarter worth approximately $13,780,000. Qube Research & Technologies Ltd grew its holdings in Arvinas by 154.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock worth $12,668,000 after acquiring an additional 903,337 shares in the last quarter. Millennium Management LLC grew its holdings in Arvinas by 208.4% during the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock worth $9,198,000 after acquiring an additional 885,483 shares in the last quarter. Finally, Balyasny Asset Management L.P. grew its holdings in Arvinas by 469.1% during the 3rd quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock worth $10,286,000 after acquiring an additional 995,125 shares in the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Price Performance

Shares of ARVN opened at $9.08 on Monday. Arvinas has a 1-year low of $6.05 and a 1-year high of $14.51. The stock has a market cap of $585.84 million, a PE ratio of -2.73 and a beta of 1.79. The firm has a 50-day simple moving average of $10.97 and a two-hundred day simple moving average of $11.69.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.05. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The business had revenue of $15.60 million during the quarter, compared to analysts’ expectations of $16.61 million. During the same period last year, the business earned $1.14 earnings per share. The business’s revenue for the quarter was down 91.7% on a year-over-year basis. As a group, sell-side analysts expect that Arvinas will post -2.85 earnings per share for the current fiscal year.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.